NCT03242473

Brief Summary

Acute pancreatitis is increasingly common diagnosis in children. Most of the guidelines related to the details of management of acute pancreatitis are extrapolated from the adult literature. There is only limited data regarding management of acute pancreatitis in children. The mainstay of management is bowel and pancreatic rest with significant fluid support to minimize the effect of the cytokines on the pancreas and other organs. The standard fluid choices are Lactated Ringer's solution (LR) and normal saline (NS). Currently, both LR and NS are used at the discretion of the treating physician as the standard of care for acute pancreatitis. The investigators hope to examine the question of ideal fluid choice for fluid resuscitation in children with acute pancreatitis by assessing recovery time in the context of measured inflammatory markers and SIRS status at 24 and 48 hours after admission. The ideal fluid choice in the initial resuscitation of acute pancreatitis has not been effectively evaluated before in the pediatric population. Even if there is no statistically significant difference between the two fluid options, this trial will still provide clinically significant information.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
79

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2014

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

August 22, 2016

Completed
12 months until next milestone

First Posted

Study publicly available on registry

August 8, 2017

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 23, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 23, 2020

Completed
Last Updated

August 17, 2021

Status Verified

August 1, 2021

Enrollment Period

5.9 years

First QC Date

August 22, 2016

Last Update Submit

August 11, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • C-Reactive Protein (CRP)

    Primary marker of inflammation, change measured at baseline and then every 24 hours for 48 hours

    At admission, 24 and 48 hours

Secondary Outcomes (6)

  • Blood Urea Nitrogen (BUN)

    At admission, 24 and 48 hours

  • Serum Amylase

    At admission, 24 and 48 hours

  • Serum Lipase

    At admission, 24 and 48 hours

  • Average length of stay

    Total length of stay in the hospital, measured in hours, usually around 4 days (96 hours).

  • Time to initiation of enteral feeds

    Total length of time to initiate feeds in the hospital, measured in hours, usually around 2 days (48 hours).

  • +1 more secondary outcomes

Study Arms (2)

Lactated Ringers (LR)

EXPERIMENTAL

The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.

Other: Fluid Management

Normal Saline (NS)

EXPERIMENTAL

The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.

Other: Fluid Management

Interventions

The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.

Also known as: Resuscitative fluids for acute pancreatitis
Lactated Ringers (LR)Normal Saline (NS)

Eligibility Criteria

Age0 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Patients aged 0-18 years diagnosed with acute pancreatitis in the emergency department or inpatient ward at Children's Hospital of The King's Daughters or one of the affiliated institutions participating in the study.

You may not qualify if:

  • Patients greater than 18 years of age
  • Patients who are not diagnosed with acute pancreatitis
  • Patients who have any previous history of acute pancreatitis, past medical history of underlying illness including congenital heart disease, chronic lung disease, or renal failure
  • Patients who have any of the following: hyperkalemia, systemic acidosis, acute dehydration, extensive tissue breakdown, adrenal insufficiency, concomitant use of potassium-sparing diuretics, use of extended-release preparations in patients with esophageal compression caused by an enlarged left atrium, hypersensitivity to sodium chloride, hypernatremia, or fluid retention
  • Patients who are pregnant females
  • Patients who have additional comorbidities at time of admission that would prevent adequate treatment with the methods described above will be excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Children's National Health System

Washington D.C., District of Columbia, 20010, United States

Location

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States

Location

Children's Hospital of The King's Daughters

Norfolk, Virginia, 23507, United States

Location

Related Publications (6)

  • Srinath AI, Lowe ME. Pediatric pancreatitis. Pediatr Rev. 2013 Feb;34(2):79-90. doi: 10.1542/pir.34-2-79. No abstract available.

    PMID: 23378615BACKGROUND
  • Sarr MG. Early fluid "resuscitation/therapy" in acute pancreatitis: which fluid? What rate? What parameters to gauge effectiveness? Ann Surg. 2013 Feb;257(2):189-90. doi: 10.1097/SLA.0b013e318280e19e. No abstract available.

    PMID: 23291660BACKGROUND
  • Meyer A, Coffey MJ, Oliver MR, Ooi CY. Contrasts and comparisons between childhood and adult onset acute pancreatitis. Pancreatology. 2013 Jul-Aug;13(4):429-35. doi: 10.1016/j.pan.2013.06.005. Epub 2013 Jun 27.

    PMID: 23890143BACKGROUND
  • Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S, Smith B, Banks PA, Conwell DL. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011 Aug;9(8):710-717.e1. doi: 10.1016/j.cgh.2011.04.026. Epub 2011 May 12.

    PMID: 21645639BACKGROUND
  • Goldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005 Jan;6(1):2-8. doi: 10.1097/01.PCC.0000149131.72248.E6.

    PMID: 15636651BACKGROUND
  • Farrell PR, DesPain AW, Farmer P, Farrell LM, Greenfield B, Rogers ME, Hornung L, Kim E, Pearman R, Neway B, Thompson T, Heubi JE, Sehgal S, Amoury R, Abu-El-Haija M. Faster discharge with lactated ringers than normal saline in first 72 h of acute pancreatitis: A multicenter randomized trial. J Pediatr Gastroenterol Nutr. 2024 Feb;78(2):360-368. doi: 10.1002/jpn3.12082. Epub 2023 Dec 11.

MeSH Terms

Conditions

Pancreatitis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System Diseases

Study Officials

  • Peter R Farrell, MD

    Children's Hospital Medical Center, Cincinnati

    PRINCIPAL INVESTIGATOR
  • Sona Sehgal, MD

    Children's National Research Institute

    PRINCIPAL INVESTIGATOR
  • Rana Ammoury, MD

    Children's Hospital of The King's Daughters

    PRINCIPAL INVESTIGATOR
  • Maisam Abu-El-Haija, MD

    Children's Hospital Medical Center, Cincinnati

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Fellow, Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition

Study Record Dates

First Submitted

August 22, 2016

First Posted

August 8, 2017

Study Start

December 1, 2014

Primary Completion

October 23, 2020

Study Completion

October 23, 2020

Last Updated

August 17, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will share

We plan to share the de-identified data obtained at CCHMC with our partners at CHKD and Children's National Medical Center, and we intend to have them share their data with us as well.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
Data will be shared for up to 3 years after the conclusion of recruitment.

Locations